Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE II-1Diabète et hypertension artérielle : prévalence et facteurs associésird-00718213, version 1 - 16 Jul 2012être associé à d'autres mesures de prévention de lamaladie cardiovasculaire (tabac, surpoids, hyperlipidémie).Pour ce faire, les modèles de suivi des PVVIHen PED doivent intégrer ces paramètres. Des conseilshygiéno-diététiques incluant le sevrage tabagique,une activité physique régulière et une alimentationéquilibrée doivent être intégrés dans la consultation deroutine de ces populations. La prise de la pressionartérielle, du tour de taille, la glycémie, la cholestérolémie,la triglycéridémie doivent également être faitsrégulièrement au moins à partir d’un certain âge et/oud’une certaine durée d’exposition aux ARV ; voire d’uncertain niveau de risque cardiovasculaire.5. RÉFÉRENCES1. UNAIDS. World AIDS day report/2011. Disponible à partir de:URL : http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf (consulté le 20/02/2012).2. OMS, ONUSIDA, UNICEF. La riposte mondiale au VIH/sida:rapport de situation 2011. Disponible à partir de : URL :http://www.who.int/hiv/pub/progress_report2011/hiv_report_summary_2011_fr.pdf (consulté le 20/02/2012).3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, FuhrerJ, Satten GA, et al. Declining morbidity and mortality amongpatients with advanced human immunodeficiency virus infection.HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar26;338(13):853-604. Deeks SG. Immune dysfunction, inflammation, and acceleratedaging in patients on antiretroviral therapy. Top HIV Med. 2009Sep-Oct;17(4):118-235. Justice AC. HIV and aging: time for a new paradigm. CurrHIV/AIDS Rep. 2010 May;7(2):69-76.6. Antiretroviral Therapy Cohort Collaboration. Life expectancy ofindividuals on combination antiretroviral therapy in high-incomecountries: a collaborative analysis of 14 cohort studies. Lancet.2008 Jul 26;372(9635):293-9.7. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, etal. Impact of late diagnosis and treatment on life expectancy inpeople with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.BMJ. 2011 Oct 11;343:d6016. doi: 10.1136/bmj.d6016.8. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE,Bacchetti P, et al. Association of HIV infection, demographic andcardiovascular risk factors with all-cause mortality in the recentHAART era. J Acquir Immune Defic Syndr. 2010 Jan;53(1):102-69. Antiretroviral Therapy Cohort Collaboration, Zwahlen M, HarrisR, May M, Hogg R, Costagliola D, de Wolf F, et al. Mortality ofHIV-infected patients starting potent antiretroviral therapy: comparisonwith the general population in nine industrialized countries.Int J Epidemiol. 2009 Dec;38(6):1624-33.10. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J,Sørensen HT, et al. Survival of persons with and without HIVinfection in Denmark, 1995-2005. Ann Intern Med. 2007 Jan16;146(2):87-9511. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, KirkO, et al. Liver-related deaths in persons infected with the humanimmunodeficiency virus: the D:A:D study. Arch Intern Med. 2006Aug 14-28;166(15):1632-41.12. Justice AC. Prioritizing primary care in HIV: comorbidity,toxicity, and demography. Top HIV Med 2006–2007;14:159-63.13. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of deathamong persons with AIDS in the era of highly active antiretroviraltherapy: New York City. Ann Intern Med 2006;145:397-406.14. Phillips AN, Neaton J, Lundgren JD. The role of HIV in seriousdiseases other than AIDS. AIDS. 2008 Nov 30;22(18):2409-18.15. Kirk JB, Goetz MB. Human immunodeficiency virus in an agingpopulation, a complication of success. J Am Geriatr Soc. 2009Nov;57(11):2129-38.16. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E,et al. Premature Age-Related Comorbidities Among HIV-InfectedPersons Compared With the General Population. Clin Infect Dis.2011 Dec;53(11):1120-6.17. Calmy A, Hirshel B, Cooper DA, Carr A. Clinical Update :adverse effects of antiretroviral therapy. The Lancet 2007, 370:12-14.18. Brinkman K., ter Hofstede H.J.M., Burger D.M., SmeitinkJ.A.M., Koopmans P.P. Adverse effects of reverse transcriptaseinhibitors : mitochondrial toxicity as common pathway. AIDS, 1998,12 : 1735-1744.19. Girard P.M., Katlama C., Pialoux G. VIH, édition 2007. DoinEditeurs, Rueil-Malmaison, France, 2007, 727 p. ISBN 978-2-7040-1231-2.20. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H,et al. T cell activation is associated with lower CD4+ T cell gains inhuman immunodeficiency virus-infected patients with sustainedviral suppression during antiretroviral therapy. J Infect Dis. 2003May 15;187(10):1534-43.21. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M,Page-Shafer K, et al. Relationship between T cell activation andCD4+ T cell count in HIV-seropositive individuals with undetectableplasma HIV RNA levels in the absence of therapy. J Infect Dis.2008 Jan 1;197(1):126-33.22. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G,Rao S, et al. Microbial translocation is a cause of systemic immuneactivation in chronic HIV infection. Nat Med. 2006Dec;12(12):1365-71.23. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ,Brun SC, et al. Low-level viremia persists for at least 7 years inpatients on suppressive antiretroviral therapy. Proc Natl Acad SciU S A. 2008 Mar 11;105(10):3879-84.24. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, HeitmanJ, et al. Induction of a striking systemic cytokine cascade prior topeak viremia in acute human immunodeficiency virus type 1infection, in contrast to more modest and delayed responses inacute hepatitis B and C virus infections. J Virol. 2009Apr;83(8):3719-33.25. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment,ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172.26. Bisson G, Gross R, Miller V, Weller I, Walker A, Arlett P, et al.Monitoring of long-term toxicities of HIV treatments: an internationalperspective. AIDS. 2003 Nov 21;17(17):2407-17.63